ClinicalTrials.gg
CompletedNCT05287360Updated Apr 18, 2022

A Study Comparing Four Different Rivoceranib Tablets in Healthy Participants

A Phase 1 interventional study of Rivoceranib in Healthy, sponsored by Elevar Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-18.

Sponsored by Elevar Therapeutics · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Mar 2022, 4 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The main purpose of this trial is to compare a single dose of 4 different rivoceranib tablets in healthy adult participants.

Read the detailed description

Participants will be randomized to 1 of 4 treatment sequences (1-4). Each participant will participate in 4 treatment periods. One formulation of rivoceranib will be administered per treatment period. Blood samples will be collected predose and up to 120 hours postdose to evaluate the pharmacokinetics (PK) of rivoceranib and its major metabolites.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Elevar Therapeutics is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must have a from 18.5 to 32.0 kilograms (kg)/meter squared (inclusive) and a weight of ≥ 50 kg at Screening.
  2. Participants must be able to provide after risks and benefits have been explained. Participants must be capable of understanding, able to sign a written informed consent, and willing to comply with the protocol requirements.
  3. Participants must agree to discontinue intake of beverages and foods known to interfere with cytochrome P450 (CYP) metabolic enzymes such as: grapefruit- and quinine-containing food and beverages (for example, tonic water, bitter lemon), orange juice, pomelos, cranberry, pomegranate, starfruit, Seville oranges (or marmalade made from them), garlic supplements or licorice, within 14 days prior to first dosing.
  4. Participants must be in general good health as determined by the principal investigator (PI), based on pre-study medical and surgical history, physical examination, and clinical laboratory tests.
  5. Participants must have normal blood pressure at Screening: systolic blood pressure \< 130 millimeters of mercury (mmHg) and diastolic blood pressure \< 85 mmHg.
  6. Participants must have no laboratory test results (≤ 1.5 x for serum and alanine aminotransferase) at Screening.
  7. Participants must have no clinically significant laboratory test results for , activated partial thromboplastin time, and international normalized ratio (> 20% outside the normal ranges) at Screening and Check-in.

Exclusion criteria

Exclusion Criteria:

  1. Participants who have participated in any study within 30 days or 5 half-lives of the test drug's biologic activity, whichever is longer, prior to the first dosing.
  2. Participants with any medical or surgical condition that may interfere with the absorption, distribution, or metabolism of the study drugs.
  3. Participants who have a history of to rivoceranib or any of its .
  4. Participants who are unwilling or unable to avoid xanthine- and caffeine-containing drinks (including many soft drinks, energy drinks, coffee, and tea) and foods (such as chocolate or coffee flavored) from 72 hours prior to first dosing.
  5. Participants unable to refrain from or anticipate the use of:

    • any non-prescription medications, herbal remedies, or vitamin supplements within 14 days prior to the first dosing
    • any investigational drugs and prescription medications within 28 days prior to the first dosing. Use of any drugs or herbal remedies known to be significant inhibitors or inducers of CYP 3A4 and 2D6 enzymes for 28 days prior to the first dosing
    • appropriate sources (for example, Flockhart Table) will be consulted to confirm lack of PK/pharmacodynamic interaction with study drugs
  6. Participants with interval by Fridericia's formula > 460 microseconds or have findings, in the opinion of the PI, at Screening.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Treatment Sequence 1

    Participants will receive rivoceranib on Day 1 of each period as a single dose under fasted conditions as follows: Period 1: Formulation 1; Period 2: Formulation 2; Period 3: Formulation 3; Period 4: Formulation 4 There will be a washout period of 5 days between each dosing.

    Drug: Rivoceranib

  • Experimental
    Treatment Sequence 2

    Participants will receive rivoceranib on Day 1 of each period as a single dose under fasted conditions as follows: Period 1: Formulation 2; Period 2: Formulation 4; Period 3: Formulation 1; Period 4: Formulation 3 There will be a washout period of 5 days between each dosing.

    Drug: Rivoceranib

  • Experimental
    Treatment Sequence 3

    Participants will receive rivoceranib on Day 1 of each period as a single dose under fasted conditions as follows: Period 1: Formulation 3; Period 2: Formulation 1; Period 3: Formulation 4; Period 4: Formulation 2 There will be a washout period of 5 days between each dosing.

    Drug: Rivoceranib

  • Experimental
    Treatment Sequence 4

    Participants will receive rivoceranib on Day 1 of each period as a single dose under fasted conditions as follows: Period 1: Formulation 4; Period 2: Formulation 3; Period 3: Formulation 2; Period 4: Formulation 1 There will be a washout period of 5 days between each dosing.

    Drug: Rivoceranib

Interventions

  • Rivoceranib will be supplied as film-coated tablets for oral administration as 4 different formulations: Formulation 1, 3, and 4 = 250 milligrams; Formulation 2 = 200 milligrams.

    Also known as: Rivoceranib Mesylate, Apatinib Mesylate

06

What researchers measure

Primary outcomes

  1. Area Under The Concentration-time Curve From Time 0 To The Last Observed Non-zero Concentration (AUC0-t) For Plasma Rivoceranib And Its Major Metabolites

    Time frame: 0 (predose) up to 120 hours postdose

  2. Area Under The Concentration-time Curve From Time 0 Extrapolated To Infinity (AUC0-inf) For Plasma Rivoceranib And Its Major Metabolites

    Time frame: 0 (predose) up to 120 hours postdose

  3. Maximum Observed Concentration (Cmax) For Plasma Rivoceranib And Its Major Metabolites

    Time frame: 0 (predose) up to 120 hours postdose

Secondary outcomes

  1. Percent Of AUC0-inf Extrapolated (AUC%extrap) For Plasma Rivoceranib And Its Major Metabolites

    Time frame: 0 (predose) up to 120 hours postdose

  2. Apparent Volume Of Distribution During The Terminal Elimination Phase After Oral (Extravascular) Administration (Vz/F) For Plasma Rivoceranib

    Time frame: 0 (predose) up to 120 hours postdose

  3. Apparent Total Plasma Clearance After Oral (Extravascular) Administration (CL/F) For Plasma Rivoceranib

    Time frame: 0 (predose) up to 120 hours postdose

  4. Apparent First-order Terminal Elimination Half-life (t½) For Plasma Rivoceranib And Its Major Metabolites

    Time frame: 0 (predose) up to 120 hours postdose

  5. Apparent First-order Terminal Elimination Rate Constant (Kel) For Plasma Rivoceranib And Its Major Metabolites

    Time frame: 0 (predose) up to 120 hours postdose

  6. Time Of Observed Cmax (Tmax) For Plasma Rivoceranib And Its Major Metabolites

    Time frame: 0 (predose) up to 120 hours postdose

  7. Participants Experiencing Treatment-emergent Adverse Events

    Time frame: Day 1 through Follow-up (14 days after the last dose of study drug)

07

Study locations

1 site
  • Celerion
    Tempe, Arizona 85283, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2021 to primary completion in Mar 2022, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2022
First posted
Mar 18, 2022
StartActual
Dec 30, 2021
Primary completionActual
Mar 16, 2022
CompletionActual
Mar 24, 2022
Last update
Apr 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05287360
Lead sponsor
Elevar Therapeutics
Responsible party
Sponsor
First posted
Mar 18, 2022
Start date
Dec 30, 2021
Primary completion
Mar 16, 2022
Completion
Mar 24, 2022
Last update
Apr 18, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apatinib

Start the discussion